Condition
Stable Vitiligo
Total Trials
4
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (2)
Early P 1 (1)
P 1 (1)
Trial Status
Completed3
Not Yet Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 3 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07690501Not ApplicableCompleted
Adipose-derived Stem Cells Combined With Excimer Light in the Treatment of Stable Vitiligo
NCT06810869Early Phase 1Not Yet RecruitingPrimary
Induced Pluripotent Stem Cell Derived Exosomes Nasal Drops for the Treatment of Stable Vitiligo
NCT03535051Not ApplicableCompletedPrimary
Efficiency of Fractional-Laser Resurfacing Followed by Topical Tacrolimus 0.03% Cream vs Tacrolimus Alone in Vitiligo
NCT01701648Phase 1CompletedPrimary
Melanocyte Transplantation for Patients With Stable Vitiligo.
Showing all 4 trials